Validating a novel driving simulation-based MWT against the standard MWT in an OSA-cohort challenged by CPAP-withdrawal (DS-MWT2) – Protocol for a monocentric, controlled, randomized, crossover trial
Abstract
Background: Excessive daytime sleepiness (EDS) is a major yet under-recognized contributor to road traffic accidents. Traditional diagnostic tools, such as the Maintenance of Wakefulness Test (MWT), assess wakefulness under passive conditions but may not accurately reflect real-world driving risks. To address this gap, we have piloted a Driving Simulation-based MWT (DS-MWT), designed to evaluate sleepiness in an ecologically valid driving scenario. The present study aims to validate the novel DS-MWT against the classical MWT in a functionally relevant cohort of patients with obstructive sleep apnoea (OSA).
Methods: The present monocentric, randomized, controlled, within-subject crossover trial will include 54 participants: 36 patients with OSA undergoing ≥ 7-day CPAP withdrawal (W) or continuation (C), and 18 healthy controls. The study employs a well-established CPAP-withdrawal model in patients with prior optimal treatment adherence to transiently induce EDS under controlled conditions. A healthy control group is included to enable between-group comparisons. The primary expected outcome is the difference in mean latencies between MWT and DS-MWT, determined during four standardized test sessions per condition. Secondary exploratory outcomes are defined as the presence, direction, and magnitude of differences or correlations between treatment status (CPAP withdrawal vs. continuation) and driving performance metrics (e.g., lateral position, speed, lane departures, etc.), EEG…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 54 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.